{
    "clinical_study": {
        "@rank": "16895", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of different combination chemotherapy\n      regimens in treating infants who have newly diagnosed neuroblastoma."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma", 
        "completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "condition": "Neuroblastoma", 
        "condition_browse": {
            "mesh_term": "Neuroblastoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Confirm that the outcome for infants with newly diagnosed stage IV or IVS neuroblastoma\n           without MYCN amplification is not altered by treatment with etoposide and carboplatin\n           followed by cyclophosphamide, doxorubicin, and vincristine.\n\n        -  Determine whether deletion of chromosome 1p or diploidy/tetraploidy are prognostic\n           factors in these patients.\n\n        -  Determine whether there are other prognostic criteria that could be used in future\n           therapeutic stratification of these patients.\n\n      OUTLINE: This is a multicenter study. Patients are stratified according to age (under 1\n      month vs over 1 month).\n\n      Infants less than 1 month of age are further stratified according to Philadelphia score\n      (less than 1 vs at least 1). Infants over 1 month of age are also further stratified\n      according to Philadelphia score (less than 2 vs at least 2).\n\n      Infants under 1 month of age with Philadelphia score of less than 1 and infants over 1 month\n      of age with Philadelphia score of less than 2 undergo observation only. Infants under 1\n      month of age with Philadelphia score of at least 1 and infants over 1 month of age with\n      Philadelphia score of at least 2 receive VP-CARBO chemotherapy.\n\n        -  VP-CARBO chemotherapy: Patients receive etoposide IV over 2 hours and carboplatin IV\n           over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses. Patients with\n           no response receive CADO chemotherapy.\n\n        -  CADO chemotherapy: Patients receive cyclophosphamide IV over 1 hour on days 1-5,\n           doxorubicin IV over 6 hours on days 4 and 5, and vincristine IV on days 1 and 5.\n           Treatment repeats every 21 days for a maximum of 4 courses.\n\n      Patients are followed within 6 months and then annually for 5 years.\n\n      PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study within 4 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed newly diagnosed stage IV or IVS neuroblastoma or\n             ganglioneuroblastoma\n\n               -  Metastases confined to marrow, skin, nodes, or liver\n\n                    -  No metastases to bone (radiologic bone lesions in skeleton), CNS, pleura,\n                       or lung\n\n          -  No MYCN amplification (i.e., fewer than 10 copies)\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Under 12 months at diagnosis\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy\n\n          -  Not specified\n\n        Chemotherapy\n\n          -  Not specified\n\n        Endocrine therapy\n\n          -  Not specified\n\n        Radiotherapy\n\n          -  Not specified\n\n        Surgery\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "1 Year", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "October 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00025610", 
            "org_study_id": "CDR0000068979", 
            "secondary_id": [
                "EURO-INF-NB-STUDY-1999-99.2", 
                "EU-20125B"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Etoposide", 
                "Vincristine", 
                "Carboplatin"
            ]
        }, 
        "keyword": [
            "disseminated neuroblastoma", 
            "stage 4S neuroblastoma"
        ], 
        "lastchanged_date": "September 16, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EURO-INF-NB-STUDY-1999-99.2"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }, 
                    "name": "St. Anna Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium", 
                        "zip": "B-9000"
                    }, 
                    "name": "Universitair Ziekenhuis Gent"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Rigshospitalet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31026"
                    }, 
                    "name": "Centre Hospitalier Regional de Purpan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genoa", 
                        "country": "Italy", 
                        "zip": "16148"
                    }, 
                    "name": "Istituto Giannina Gaslini"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0027"
                    }, 
                    "name": "Rikshospitalet University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisboa", 
                        "country": "Portugal", 
                        "zip": "1099-023 Codex"
                    }, 
                    "name": "Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46009"
                    }, 
                    "name": "Hospital Universitario LA FE"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden", 
                        "zip": "41685"
                    }, 
                    "name": "Ostra Sjukhuset"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "BS2 8BJ"
                    }, 
                    "name": "Bristol Royal Hospital for Children"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "S10 2TH"
                    }, 
                    "name": "Children's Hospital - Sheffield"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Denmark", 
                "France", 
                "Italy", 
                "Norway", 
                "Portugal", 
                "Spain", 
                "Sweden", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "official_title": "European Infant Neuroblastoma Study - Stage 4S and Stage 4 (No Bone, Lung, Pleura or CNS); MYCN Not Amplified", 
        "overall_official": {
            "affiliation": "Children's Hospital - Sheffield", 
            "last_name": "Mary P. Gerrard, MBChB, FRCP, FRCPCH", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "19171711", 
            "citation": "De Bernardi B, Gerrard M, Boni L, Rubie H, Ca\u00f1ete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol. 2009 Mar 1;27(7):1034-40. Epub 2009 Jan 26."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00025610"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Infant Neuroblastoma Study Group - 1999", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2001"
    }, 
    "geocoordinates": {
        "Bristol Royal Hospital for Children": "51.455 -2.588", 
        "Centre Hospitalier Regional de Purpan": "43.605 1.444", 
        "Centre Hospitalier Universitaire Vaudois": "46.52 6.634", 
        "Children's Hospital - Sheffield": "53.381 -1.47", 
        "Hospital Universitario LA FE": "39.47 -0.377", 
        "Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.": "38.707 -9.136", 
        "Istituto Giannina Gaslini": "44.407 8.934", 
        "Ostra Sjukhuset": "57.709 11.975", 
        "Rigshospitalet": "55.676 12.568", 
        "Rikshospitalet University Hospital": "59.914 10.752", 
        "St. Anna Children's Hospital": "48.208 16.374", 
        "Universitair Ziekenhuis Gent": "51.053 3.73"
    }
}